WO2023140809 - NOVEL POLYMORPH OF VISMODEGIB AND METHOD OF PREPARATION
National phase entry:
Publication Number
WO/2023/140809
Publication Date
27.07.2023
International Application No.
PCT/TR2022/050047
International Filing Date
20.01.2022
Title **
[English]
NOVEL POLYMORPH OF VISMODEGIB AND METHOD OF PREPARATION
[French]
NOUVEAU POLYMORPHE DE VISMODÉGIB ET PROCÉDÉ DE PRÉPARATION
Applicants **
DEVA HOLDING
Inventors
HAAS, Philipp Daniel
STECKEL, Hartwig Andreas
BELLUR ATİCİ, Esen
BAŞLAR, Yıldıray
KESKİN, Elif
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1885 | |
| EPO | Filing, Examination, Granting | 9151 | |
| Japan | Filing, Examination, Granting | 1783 | |
| South Korea | Filing, Examination, Granting | 1244 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,803
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a new crystalline form of vismodegib, a methanol-solvate of vismodegib, namely Form S, and methods for its preparation. The vismodegib Form S is characterized by an XRPD pattern having characteristic peaks (2theta ± 0.2º) at 7.1, 14.0, 16.7, 19.1, 22.3, 24.6 and 28.0. The present invention also provides interconversion process of vismodegib Form S to crystalline vismodegib Form B, pharmaceutical compositions comprising vismodegib Form S, and medical use of vismodegib Form S.[French]
La présente invention concerne une nouvelle forme cristalline de vismodégib, un solvate de méthanol de vismodégib, à savoir la forme S, ainsi que des procédés pour sa préparation. La forme S de vismodégib est caractérisée par un diagramme XRPD ayant des pics caractéristiques (2 thêta ± 0,2°) à 7,1, 14,0, 16,7, 19,1, 22,3, 24,6 et 28,0. La présente invention concerne également un procédé d'interconversion de forme S de vismodégib en forme B de vismodégib cristalline, des compositions pharmaceutiques comprenant une forme S de vismodégib, et une utilisation médicale de la forme S de vismodégib.